PDCD1 and melanoma: Analysis of a previously published melanoma proteomics dataset [14] also confirmed that expression of the MHC-I invariant chain B2M was significantly higher in pre-treatment biopsies derived from 39 melanoma patients responding to anti-PD-1 monotherapy compared to 33 non-responding patients (Supplementary Figure S2f).